Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Monday 21 June, 2010

Lipoxen PLC

Further PolyXen® Technology P

RNS Number : 9059N
Lipoxen PLC
21 June 2010
 



FOR IMMEDIATE RELEASE

21 June 2010

 

 

Lipoxen plc

('Lipoxen' or 'the Company')

 

Further PolyXen® Technology Patent

 

- PolyXen® patent family strengthened and extended into 2025 -

 

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that its monofunctional PSA PolyXen technology grant has been allowed. The patent extends the PolyXen® technology patent family in the US giving both Lipoxen and its license partners additional patent protection into 2025.

 

The monofunctional PSA technology is similar to Lipoxen's other PolyXen® technologies as it enables the attachment of polysialic acid (PSA, a polymer occurring naturally in humans) to a therapeutic protein, thereby extending its active life. This process is known as polysialylation and improves drug performance and longer circulation time of the drug in the body. The resulting conjugate molecules are biodegradable, non-immunogenic and non-toxic, and therefore are expected to avoid the toxicity attributed to other methods of extending active life, such as the use of polyethylene glycol in PEGylated protein drug candidates.

 

Importantly, this new patent means that Lipoxen's PolyXen® patent family now covers the creation of therapeutic conjugates utilising both the reducing end, as well as the non-reducing end, such methodologies having been shown in tests completed prior to both pre-clinical studies and clinical trials to avoid the problem of side product contamination.

 

Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "This new PolyXen®technology patent will protect Lipoxen's novel polysialylationtechnology into 2025. By applying this novel technology to its partners' therapeutic proteins, it is in the unique position delivering the benefits of polysialylation such as extending its active life plus the advantage of avoiding final product contamination. This forms an important part of Lipoxen's strategy to build its patent portfolio and secure long term value in the US, world's largest pharmaceutical market."

 

- Ends -

 

For further information, please contact:

Enquiries 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEVLFFBQFZBBL